DHHS Adult ARV Guidelines
Interaction Color Code
Clinical Bottom Line
Minimal data to guide interaction: weigh risks and benefits of using this combination
Drug 1
Drug 2
Mechanism
Inhibition of CYP3A4 by lenacapavir
Clinical Effects
Potential increased risk of eplerenone adverse effects
Management
If coadministering in the setting of post-MI heart failure, eplerenone dose not to exceed 25 mg daily. If coadministered for hypertension, initiate eplerenone at 25mg daily. Dose not to exceed 25 mg twice daily.
Info Source
